Comparison between GP and MVP regimen for adanced Non-small cell lung cancer

Objective To compare the efficacy and toxicity between GP (Gemcitabine + Cisplatin) regimen and MVP (Mitomycin+Vindesine + Cisplatin) regimen in the treatment of advanced Non-small Cell Lung Cancer. [Methods] Seventy-five cases of NSCLC were enrolled .Among them,42 cases were treated with GP regimen. (GEM 1.0 g/m 2 ivgtt d1,8, DDP 25 mg/m 2 ivgtt d 1-3). Of 33 cases were treated with MVP regimen (MMC 8 mg/m 2 iv di,VDS 3 mg/m 2 ivgtt di,8 DDP 25 mg/m 2 ivgtt d 1-3).The patients in two groups were repeatedly treated every 3 weeks and evaluated the efficacy after 2 cycles. [Results] For the cases with GP regimen ,the overall response rate was 57.1% with complete response 4 cases and partial response 20 cases. For the cases with MVP regimen the overall response rate was 36.4% with complete response 1 case and with partial response 11 cases . There was significant difference between two groups (P0.05) . Major toxicity is myelosuppression. The thrombocytopenia for GP regimen is higher than MVP regimen (40.5% versus 27.3%). The leucocytopenia for MVP regimen is higher than GP regimen (72.7% versus 50.0 %) (P0.05). [Conclusion] GP than MVP regimen for advanced NSCLC shows a good curative effect and low toxicity. It deserves further clinical application.